期刊
EBIOMEDICINE
卷 79, 期 -, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.ebiom.2022.104001
关键词
Ovarian cancer; Biomarker; Multi-omics; Translational medicine
资金
- National Natural Science Foundation of China (NSFC) [81672610, 81521002]
- Clinic + X program of Peking University
- China Postdoctoral Science Foundation [2021M700289]
- Boya postdoctoral program of Peking University
This review summarizes the recent advances and perspectives in the use of multi-omics technologies in ovarian cancer research, highlighting their potential applications in identifying novel biomarkers and improving clinical assessments.
Ovarian cancer (OC) is a heterogeneous disease with the highest mortality rate and the poorest prognosis among gynecological malignancies. Because of the absence of specific early symptoms, most OC patients are often diagnosed at late stages. Thus, improved biomarkers of OC for use in research and clinical practice are urgently needed. The last decade has seen increasingly rapid advances in sequencing and biotechnological methodologies. Consequently, multiple omics technologies, including genomic/transcriptomic sequencings and proteomic/metabolomic mass spectra, have been widely applied to analyze tissue-and liquid-derived samples from OC patients. The integration of multi-omics data has increased our knowledge of the disease and identified valuable OC biomarkers. In this review, we summarize the recent advances and perspectives in the use of multi-omics technologies in OC research and highlight potential applications of multi-omics for identifying novel biomarkers and improving clinical assessments. Copyright (C) 2022 The Author(s). Published by Elsevier B.V.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据